2269.HK | Ticker Profile

2269.HK

WuXi Biologics (Cayman) Inc.

Healthcare · ·

$30.38

Data: 2026-05-28

✓ ETHICAL PASS

STRONG MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$17.1B

Total market value of the company

Trailing P/E

24.16

Premium valuation

Forward P/E

16.49

Based on estimated future earnings — lower means cheaper

Rev Growth

+17.2%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC.

Country: China Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

N/A

Core business does not involve prohibited activities

Debt Ratio

0.0%

Debt must be below 33% of total assets

Cash Ratio

0.0%

Interest-bearing cash below 33% of assets

Receivables

0.0%

Receivables below 49% of assets

Revenue Purity

0.0%

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$2.57

What our model estimates this business is worth per share

Margin of Safety

-1,084.4%

Trading above fair value — no margin of safety

Rating

Overall assessment combining ethics, valuation, and quality

Percentile

59.4th

Ranks in the top 41% of our 13,571 screened universe

Ethical Score

N/A

Valuation Score

61.0

Quality Score

48.8

Combined

42.5

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.210

Excellent risk-adjusted returns

Kelly Fraction

0.0775

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.892

Returns exceed worst-case losses — strong risk profile

Annual Return

70.9%

Historical annualised return based on price data

Max Drawdown

-37.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

259

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.17

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

33.1%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go